Replies to post #111265 on Anavex Life Sciences Corp (AVXL)

[A_Good_Day_2]

I think that success and approval for 2-73 for Rett or PD would propel the stock. I'm not basing that on revenue, I'm basing it on speculation that since it works for one it should work for AD, especially with such good results from the non-confirmatory phase 2a.

There would be every reason to think that AD would be a success also.

[nidan7500]

IMO, Dr. M. chose Rett trial to go first b/c of the dramatic positive impact which might be generated. I also believe that end points for A2-73 trials are likely to include patients condition as much as they will test scores (MMSE example). Quality of life will be huge as a key metric for the new FDA trials acceptance criteria, IMO.

It will be refreshing if we have patients being interviewed about how they are feeling vs a caregiver discussion on their deepening state misery.

Is it too far down the road? Maybe, but Rett results may present results that put the critics to rest. IMO, that is why he picked it to go first.

[ExtremelyBullishZig]

Dr. Missling already stated the fastest way to market is his goal. It can be used off label and generate revenue and promise.